Using Acceleration Levers to Expedite Late Phase CMC Programs for Therapeutic Proteins

The biopharma industry is increasingly embracing the concept of ‘Acceleration Levers’ to optimize timelines and expedite time to market, as late-phase chemistry, manufacturing and controls (CMC) programs often face delays that jeopardize speed to market and strain development resources. This webinar explores strategies for reducing late-phase CMC timelines for mammalian and microbial-derived therapeutic proteins.

Want to catch up on what you missed? Watch below.